Elacestrant
Elacestrant
Elacestrant (pronounced as e-lace-strant) is a novel, oral selective estrogen receptor degrader (SERD) that is currently being studied for its potential use in the treatment of estrogen receptor positive (ER+) breast cancer.
Etymology
The term "Elacestrant" is a coined name for this specific drug, and does not have a known etymology.
Usage
Elacestrant is being developed as a potential therapeutic option for patients with ER+ breast cancer, including those who have previously received other treatments. It works by binding to the estrogen receptor and degrading it, thereby inhibiting the growth of cancer cells that depend on estrogen for their growth.
Related Terms
- Selective estrogen receptor degrader (SERD): A type of drug that binds to the estrogen receptor and degrades it, thereby inhibiting the growth of cancer cells that depend on estrogen for their growth.
- Estrogen receptor positive (ER+): A term used to describe cancer cells that have receptors (proteins) to which estrogen will bind. These cancers are often more responsive to hormone therapy.
- Breast cancer: A type of cancer that forms in the cells of the breasts. It is the most common cancer in women worldwide.
See Also
External links
- Medical encyclopedia article on Elacestrant
- Wikipedia's article - Elacestrant
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski